Key points are not available for this paper at this time.
Chronic kidney disease, HF, and type 2 diabetes mellitus (DM) are common and interrelated. Although both low eGFR and high eGFR have been associated with an increased risk of cardiovascular disease in patients with DM, it is unclear whether this association differs according to glucose tolerance. Thus, we aimed to clarify the association between eGFR and the incidence of new-onset HF according glucose tolerance status in the same cohort. Study participants underwent medical checkups between 2008 and 2019. Based on glucose tolerance status they were divided into three groups (normoglycemia n=510,300, prediabetes n=222,327 or DM n=42,903). Participants were also classified by eGFR level. Risk for HF was analyzed by a multivariate Cox regression model. During a median follow-up period of 4.4 y, 362 cases of HF occurred. Compared with 60≤ eGFR 90, the risk of HF significantly increased in those with eGFR ≥105 in people with prediabetes and DM. However, this association was not observed in those with normoglycemia (Table). In addition, both participants with DM and eGFR ≥105 and with DM with eGFR 60 had an approximately 6-fold higher risk for HF than persons with normoglycemia and 60≤ eGFR 90. Results suggested HF risk may be increased by hyperfiltration accompanied with glucose abnormality. Further studies are required to clarify the mechanisms underlying this relationship. Disclosure Y. Uegami: None. K. Fujihara: None. H. Takizawa: None. M. Kitazawa: None. H. Suzuki: None. T. Osawa: None. Y. Matsubayashi: None. T. Yamada: None. S. Kodama: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd. C. Shimayama: Employee; Kowa Company, Ltd.
UEGAMI et al. (Fri,) studied this question.